Literature DB >> 19187823

Coding variant I62V in the complement factor H gene is strongly associated with polypoidal choroidal vasculopathy.

Naoshi Kondo1, Shigeru Honda, Shin-ichi Kuno, Akira Negi.   

Abstract

PURPOSE: To investigate whether variants in the complement factor H (CFH) gene are associated with polypoidal choroidal vasculopathy (PCV).
DESIGN: Cross-sectional study. PARTICIPANTS: A case-control group of 130 PCV subjects and 173 unrelated controls.
METHODS: We conducted an association analysis between CFH variants and PCV in a Japanese population, genotyping 12 tag single nucleotide polymorphisms (SNPs)-including rs3753394, rs800292 (I62V), and rs1061170 (Y402H)-that are highly representative of the common genetic variation in the CFH region. Genotyping was performed using TaqMan technology. MAIN OUTCOME MEASURES: Allele and haplotype frequencies of the CFH variants.
RESULTS: A highly significant association with PCV was observed across the CFH region. The strongest association was observed at I62V (P = 1.7 x 10(-7)). Six other SNPs (rs3753394, rs6680396, rs1410996, rs2284664, rs1329428, and rs1065489) also showed significant association (10(-3) < P < 10(-6)). These associations became nonsignificant after accounting for rs800292 in a conditional logistic regression analysis. A significant omnibus haplotype association was detected in the entire CFH region (omnibus P = 1.6 x 10(-5) at 7 degrees of freedom). Conditional haplotype-based likelihood ratio tests revealed that the significant omnibus haplotype association disappeared when it was estimated conditional on I62V (omnibus P = 0.20, 6 degrees of freedom, post-I62V dependency), whereas the omnibus haplotype association remained significant when it was estimated conditional on any SNP other than I62V. These findings indicate that multiple observed effects were caused by linkage disequilibrium with I62V, and that this variant fully accounts for the association signals observed at the set of SNPs examined at this locus.
CONCLUSIONS: The present study provides evidence that the complement pathway plays a substantial role in the pathogenesis of PCV. The nonsynonymous variant I62V is a plausible candidate for a causal polymorphism leading to the development of PCV, given its potential for functional consequences on the CFH protein and our own statistical evidence. FINANCIAL DISCLOSURE(S): The authors have to proprietary or commercial interest in any materials discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187823     DOI: 10.1016/j.ophtha.2008.11.011

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids.

Authors:  Peter X Shaw; Li Zhang; Ming Zhang; Hongjun Du; Ling Zhao; Clara Lee; Seanna Grob; Siok Lam Lim; Guy Hughes; Janet Lee; Matthew Bedell; Mark H Nelson; Fang Lu; Martin Krupa; Jing Luo; Hong Ouyang; Zhidan Tu; Zhiguang Su; Jin Zhu; Xinran Wei; Zishan Feng; Yaou Duan; Zhenglin Yang; Henry Ferreyra; Dirk-Uwe Bartsch; Igor Kozak; Liangfang Zhang; Feng Lin; Hui Sun; Hong Feng; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-08       Impact factor: 11.205

2.  Gene-gene interaction of CFH, ARMS2, and ARMS2/HTRA1 on the risk of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese population.

Authors:  L Huang; Q Meng; C Zhang; Y Sun; Y Bai; S Li; X Deng; B Wang; W Yu; M Zhao; X Li
Journal:  Eye (Lond)       Date:  2015-03-13       Impact factor: 3.775

3.  Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Masahiro Miyake; Kenji Yamashiro; Sotaro Ooto; Akio Oishi; Isao Nakata; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-30       Impact factor: 3.117

Review 4.  Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V polymorphisms with retinal angiomatous proliferation compared with typical age-related macular degeneration: a meta-analysis.

Authors:  Mohammad Hossein Jabbarpoor Bonyadi; Mehdi Yaseri; Mortaza Bonyadi; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2016-12-22       Impact factor: 2.031

5.  Plasma biomarkers of oxidative stress and genetic variants in age-related macular degeneration.

Authors:  Milam A Brantley; Melissa P Osborn; Barton J Sanders; Kasra A Rezaei; Pengcheng Lu; Chun Li; Ginger L Milne; Jiyang Cai; Paul Sternberg
Journal:  Am J Ophthalmol       Date:  2011-10-29       Impact factor: 5.258

6.  Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Jane Z Kuo; Tien Y Wong; Frank S Ong
Journal:  Expert Rev Ophthalmol       Date:  2013-04-01

7.  Monozygotic twins with polypoidal choroidal vasuculopathy.

Authors:  Shigeki Machida; Tomomi Takahashi; Norimoto Gotoh; Nagahisa Yoshimura; Takamitsu Fujiwara; Dajiro Kurosaka
Journal:  Clin Ophthalmol       Date:  2010-07-30

8.  Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Masahiro Miyake; Kenji Yamashiro; Sotaro Ooto; Akio Oishi; Hideo Nakanishi; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-25       Impact factor: 3.117

9.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

10.  SERPING1 polymorphisms in polypoidal choroidal vasculopathy.

Authors:  Meng Li; Feng Wen; Chengguo Zuo; Xiongze Zhang; Hui Chen; Shizhou Huang; Guangwei Luo
Journal:  Mol Vis       Date:  2010-02-16       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.